Preserving Bayh-Dole—the “Inspired” Law That Underpins U.S. Leadership in Life-Sciences Innovation

ITIF commends NIST for taking steps to codify the clearly proscribed and intentionally limited intent and parameters of march-in rights as they pertain to the Bayh-Dole Act.

Comments to NIST on Rights to Federally Funded Inventions

NIH-funded research played a part in the development of 18 FDA-approved therapies between 2000 and 2020, investing $670 million. By comparison, private firms invested $44.28 billion in these therapies, 66 times more than the federal government.

Fact of the Week: In the 18 FDA-Approved Therapies Developed With NIH Grants, Private Funding Was 66 Times Greater Than NIH Investment

Misusing Bayh-Dole “March-In Right” Could Result in Fewer New Drugs, New Report Shows

Misusing Bayh-Dole "March-In Right" Could Result in Fewer New Drugs, New Report Shows

America’s world-leading life-sciences innovation system is a product of myriad policies, but one that is all too often overlooked is the Bayh-Dole Act, which gives IP rights to universities that produce innovation with federally funded R&D.

‘March-In’ Advocates Continue the Assault on Life-Sciences Innovation System

'March-In' Advocates Continue the Assault on Life-Sciences Innovation System

The unintended exploitation of Bayh-Dole “march-in” rights would significantly harm biomedical innovation, writes Stephen Ezell in Innovation Files.

Why Exploiting Bayh-Dole “March-In” Provisions Would Harm Medical Discovery

Why Exploiting Bayh-Dole "March-In" Provisions Would Harm Medical Discovery

ITIF hosted a panel discussion with leading experts on innovation policy, technology transfer, and business, who spoke to the practical implications of exercising federal “march-in” rights and why it would be a grave and ill-timed mistake for the U.S. health, competitiveness, and research landscape.

How Using March-in Rights Would Threaten America’s Research Universities

How Using March-in Rights Would Threaten America's Research Universities

The technology-transfer regime the United States has implemented over the past four decades, largely as enabled through the Bayh-Dole Act, has been tremendously effective in stimulating innovation, especially in the life sciences. While all such processes should be continuously streamlined or tweaked where improvement is possible, the current system does not need serious modification or reform.

Comments to the National Institutes of Health on “Maximizing NIH’s Levers to Catalyze Technology Transfer”

Comments to the National Institutes of Health on "Maximizing NIH's Levers to Catalyze Technology Transfer"

Universities play a pivotal role in America’s technology economy, serving as a crucial source of research, inventions, patents, start-up technology companies, and regional economic and employment growth. The Bayh-Dole Act has played an instrumental role in spurring academic technology transfer activities that serve as vital drivers of American innovation.

To Do: Defend the Bayh-Dole Act

Recommendation

Details

Editors’ Recommendations

The Bayh-Dole Act’s Vital Importance to the U.S. Life-Sciences Innovation System

Related

Preserving Bayh-Dole—the “Inspired” Law That Underpins U.S. Leadership in Life-Sciences Innovation

Comments to NIST on Rights to Federally Funded Inventions

Fact of the Week: In the 18 FDA-Approved Therapies Developed With NIH Grants, Private Funding Was 66 Times Greater Than NIH Investment